for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ビジネス

Breakingviews TV: Knockout drug

Bristol-Myers Squibb has taken a step toward closing its deal for Celgene with the $13 bln sale of the latter’s psoriasis drug to Amgen. Richard Beales says the rich price lends credence to Bristol-Myers’ claim that Celgene was undervalued, and deserving of its $74 bln offer.

最新のビデオ
エンタテインメント
世界のこぼれ話
スポーツ

ビジネス

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up